Technical Notices For A ‘No-Deal' Brexit

The UK Government has issued a series of 'technical notices' today outlining how businesses should prepare in the event of a no deal Brexit. Some of the technical notices are particularly relevant to the life science sector, including notices on the regulation of medicines, medical devices and clinical trials, submitting regulatory information on medical products and batch testing medicines.  

The medicines, medical devices and clinical trials technical notices includes information relevant to intellectual property (IP) practitioners:

• The notice outlines how the UK plans to deal with Marketing Authorisations (MAs). Current granted EU Centralised MAs will be converted into UK MAs via a grandfathering procedure. Centralised MAs which have been submitted but have not yet been granted will need to be resubmitted as a UK MA, but the UK has suggested the MHRA will take EU Committee for Medicinal Products for Human Use (CHMP) opinions into account.